Author:
Hochhaus A,Masszi T,Giles F J,Radich J P,Ross D M,Gómez Casares M T,Hellmann A,Stentoft J,Conneally E,García-Gutiérrez V,Gattermann N,Wiktor-Jedrzejczak W,le Coutre P D,Martino B,Saussele S,Menssen H D,Deng W,Krunic N,Bedoucha V,Saglio G
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference34 articles.
1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872–884.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, v1.2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf (last accessed 6 December 2016).
3. Boquimpani CM, Szczudlo T, Mendelson E, Benjamin K, Masszi T . Attitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR). Blood 2014; 124, (abstract 4547).
4. Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 2016; 101: 717–723.
5. Ross D, Villemagne-Sanchez L, Hall K, Gough K, Kashima Y, O'Callaghan C et al. Factors that influence patient willingness to attempt treatment-free remission in chronic myeloid leukaemia. Haematologica 2016; 101: 238.